Physician profile
Laura Farhat
NPI 1194937102
$1,519.35
in general payments reported to CMS, 2019-2025
12 companies · $139 in 2025
The $139 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $776 · 2022: $19.33 · 2023: $100 · 2024: $485 · 2025: $139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $724.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $724.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $436.00 | 2021 | |
| Abbvie INC. | $219.41 | 2021-2024 | |
| Novo Nordisk INC | $217.42 | 2021-2024 | Wegovy |
| Amgen INC. | $155.31 | 2021-2025 | |
| Lilly USA, LLC | $146.12 | 2021 | |
| Hologic Sales and Service, LLC | $95.20 | 2024 | Aptima |
| Gilead Sciences, INC. | $85.02 | 2024 | Epclusa |
| Corium, LLC | $78.48 | 2023 | Azstarys |
| Glaxosmithkline, LLC. | $25.22 | 2024 | Arexvy, Shingrix, Bexsero |
| Dynavax Technologies Corporation | $21.65 | 2023 | Heplisav-B |
| Astrazeneca Pharmaceuticals LP | $20.19 | 2021 | |
| Merck Sharp & Dohme LLC | $19.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Farhat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.